Publications

5813 Results

Efficacy and Safety of Cabozantinib for Advanced Gastrointestinal Neuroendocrine Tumors (NET) after Progression on Prior Therapy: A Subgroup Analysis of the Phase III CABINET Trial (Alliance A021602)

Authors
J Strosberg;T Zemla;S Geyer;M Knopp;S Behr;S Pulsipher;J Acoba;A Shergill;E Wolin;T Halfdanarson;B Konda;N Trikalinos;B Tawfik;N Raj;S Shaheen;N Vijayvergia;A Dasari;E O'Reilly;J Meyerhardt;J Chan
Journal / Conference
ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA), abstract 666
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021602

Approach to Treatment of Metastatic Hormone Sensitive Prostate (mHSPC) Cancer Among Cooperative Oncology Groups in North America

Authors
C Chalker;M Ong;R McKay;S Gulati;C Tangen;S Lerner;T Dorff;A Sokolova
Journal / Conference
ASCO GU Cancers Symposium (Feb 13-15, 2025, San Francisco, CA), poster
Year
2025
Research Committee(s)
Genitourinary

A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937- Updated Design

Authors
S Sadeghi;M Plets;P Lara;C Tangen;S Berg;J Brown;R Bangs;D Nakagawa;S Daneshmand;I Thompson;T Flaig;D Petrylak;S Lerner
Journal / Conference
ASCO GU Cancers Symposium (Feb 13-15, 2025, San Francisco, CA), Trials in Progress, TPS887
Year
2025
Research Committee(s)
Genitourinary
Study Number(s)
S1937

Secondary analysis of SWOG S1316 shows improved survival with surgical intervention for malignant bowel obstruction

Authors
J Lee;R Krouse
Journal / Conference
Society for Surgical Oncology Annual Meeting (March 27-29, 2025, Tampa, FL)
Year
2025
Research Committee(s)
Palliative Care
Study Number(s)
S1316

Presence of Ascites in the Setting of Malignant Bowel Obstruction Leads to Shorter Survival

Authors
K Dougherty;J Lee;J Deneve
Journal / Conference
Society for Surgical Oncology Annual Meeting (March 27-29, 2025, Tampa, FL)
Year
2025
Research Committee(s)
Palliative Care
Study Number(s)
S1316

Evaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial

Authors
A Sokolova;C Tangen;M Hussain;C Sweeney;T Dorff;I Thompson;S Lerner
Journal / Conference
ASCO GU Cancers Symposium (Feb 13-15, 2025, San Francisco, CA), poster, abstract 268
Year
2025
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-9346

Effect of finasteride on urinary outcomes after benign prostatic hyperplasia surgery: secondary analysis of the Prostate Cancer Prevention Trial

Authors
C Chestnut;C Yang;J Gore;J Schenk
Journal / Conference
American Urological Association Annual Meeting (April 26-29 (Saturday-Tuesday, Las Vegas NV)
Year
2025
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Efficacy and Safety of Cabozantinib for Advanced Grade 3 Neuroendocrine Tumors After Progression on Prior Therapy: Subgroup Analysis of the Phase 3 CABINET Trial (Alliance A021602)

Authors
J Strosberg;T Zemla;S Geyer;S Pulsipher;S Behr;N Raj;N Vijayvergia;NA Dasari;J Meyerhardt;E Wolin;T Halfdanarson;J Chan
Journal / Conference
ENETS (European Neuroendocrine Tumor Society) meeting (Mar 5-7, 2025, Krakow, Poland)
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021602

Prognostic and predictive role of T cell infiltration in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702

Authors
Y Takashima;C Ma;Q Shi;A Dias Costa;T Twombly;J Vayrynen;M Zhao;A Shergill;P Kumar;F Couture;P Kuebler;S Krishnamurthi;B Tan;E O'Reilly;A Shields;S Ogino;C Fuchs;J Meyerhardt;J Nowak
Journal / Conference
AACR Annual Meeting (April 25-30, 2025, Chicago, IL)
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

Harnessing Artificial intelligence in Data Management

Authors
C Cook;A Hoering;M LeBlanc
Journal / Conference
Society for Clinical Trials (May 18-21, 2025, Vancouver, CAN)
Year
2025
Research Committee(s)
Multiple sites